読み込み中
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
前日終値
$19.00
+$0.88 · +4.86%
日中の時刻はETです。市場データは遅延する場合があります。
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
日中レンジ
現在 $19.00
52週レンジ
現在 $19.00
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
38
割高
センチメント
56
まちまち
リスク
52
やや高いリスク
モメンタム
42
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
日中レンジ
現在 $19.00
52週レンジ
現在 $19.00
| 指標（USD） | 2025年度 |
|---|---|
| 売上高 | 297.6万 USD |
| 粗利益 | 297.6万 USD |
| 研究開発 | 1.27億 USD |
| 販売・一般管理 | 3751.6万 USD |
| 営業費用 | 1.64億 USD |
| 受取利息 | 634.8万 USD |
| 支払利息 | 1.7万 USD |
| 減価償却費と償却費 | 491.1万 USD |
| 営業利益 | −1.61億 USD |
| 純利益 | −1.49億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$39.00
上昇余地（105.26%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1302.25万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM782.33万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF442.74万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO163.93万0.01%139.17億 USD0.24%$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA151.9万0.01%218.24億 USD0.03%$32.79+0.40%
iShares Micro-Cap ETFIWC95万0.07%13.17億 USD0.60%$183+0.11%
Vanguard Russell 2000 ETFVTWO29.14万0.00%180億 USD0.06%$112.66+0.50%
Schwab U.S. Broad Market ETFSCHB23.01万0.00%453.77億 USD0.03%$29.91+0.61%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCVanguard Russell 2000 ETFVTWOSchwab U.S. Broad Market ETFSCHBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
